Sanofi plans to transfer 20 established drugs, 3 plants to Cheplapharm for 26.4% stake
SNY•Guidance impact
Sanofi expects no impact on its 2026 financial guidance from the planned transaction.
Deal timing and approvals
Full closing is targeted for Q3 2027, subject to regulatory clearances and employee consultation processes.
Sanofi to take stake in Cheplapharm
Sanofi will take a 26.4% stake in Cheplapharm as part of the deal; assets include Lovenox/Clexane outside the US.
Planned transfer of drugs and plants
Sanofi plans to transfer 20 established medicines from Sanofi, alongside three manufacturing sites, under a new strategic partnership.
Assets include plants in Csanyikvölgy, Hungary, Jurong, Singapore, and Ploërmel, France; portfolio transfer set to start in Q1 2027.
